title: [Immunomodulating, antioxidant and hepatoprotective effects of immobilized dosage forms of rifampicin and cephalexin].
abstract: The aim of the study was to lower the immunosuppressory, prooxidant and hepatotoxic effects of rifampicin and cephalexin by their immobilization in erythrocyte vehicles. The experiments were performed on Wistar rats with the use of rifampicin, cephalexin and lysozyme (ZAO Ferane) and hemodes (6% aqueous saline solution of low molecular polyvinylpyrrolidone, mol. wt. 12600+/-2700). Rifampicin- and cephalexin-entrapped erythrocytes were prepared. Spectrophotometric procedures for quantitative assay of the immobilized antibiotics were developed. The impact of the solution concentration and incubation time on the level of the antibiotic entrapping was studied. The erythrocyte vehicles were shown to be able to entrap the antibiotics for 9 days and to preserve their stability for 24 hours. It was observed that the increase of the immunosuppressory, prooxidant and hepatotoxic effects of the antibiotics administered without the vehicles to the laboratory animals infected by staphylococci was dose-dependent. The use of the antibiotics entrapped in the erythrocyte vehicles stimulated the immune reactivity of the animals and normalized the indices of lipid peroxidation, the antioxidant system, cytolysis and cholestasis.
authors.forename: L G
authors.initials: LG
authors.lastname: Prokopenko
authors.forename: A L
authors.initials: AL
authors.lastname: Lazarev
authors.forename: G V
authors.initials: GV
authors.lastname: Siplivyĭ
authors.forename: A V
authors.initials: AV
authors.lastname: Kukureka
authors.forename: L E
authors.initials: LE
authors.lastname: Siplivaia
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use; D002506:Cephalexin / Q000008:administration & dosage* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D004353:Drug Evaluation, Preclinical; D004912:Erythrocytes; D022781:Hepatocytes / Q000378:metabolism; D007273:Injections, Intramuscular; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D018655:Lymphocyte Count; D051381:Rats; D017208:Rats, Wistar; D012293:Rifampin / Q000008:administration & dosage* / Q000627:therapeutic use; D013154:Spleen / Q000276:immunology; D013211:Staphylococcus aureus
chemical_list: D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D000975:Antioxidants; D004337:Drug Carriers; D002506:Cephalexin; D012293:Rifampin